Charité - Universitätsmedizin Berlin

CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany (2022) Bader P, Rossig C, Hutter M, Ayuk FA, Baldus CD, Buecklein VL, Bonig H, et al. Conference contribution Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group (2022) Burchert A, Saussele S, Michel C, Metzelder SK, Hochhaus A, Gattermann N, Crysandt M, et al. Conference contribution Outcome of 841 Older Patients (> 55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (2022) Goekbuget N, Viardot A, Steffen B, Hahn J, Spriewald B, Martin S, Raffel S, et al. Conference contribution Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time (2022) Rejeski K, Perez AP, Iacoboni G, Buecklein VL, Blumenberg V, Völkl S, Penack O, et al. Conference contribution ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (2022) Ernst T, Schoenfeld L, Rinke J, Hinze A, Nagel SN, Schaefer V, Schenk T, et al. Conference contribution S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid (2022) Hofmann SC, Gunther C, Bockle BC, Didona D, Ehrchen J, Gaskins M, Geerling G, et al. Journal article ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, et al. Journal article, Editorial LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT (2022) Weller J, Zeyen T, Schlegel U, Lazaridis L, Werner JM, Onken J, Zeiner P, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution